Baclofen: Mechanism of Action, Uses, Side Effects

Mechanism of action

Baclofen is a structural analog of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system. Unlike GABA itself, baclofen readily crosses the blood-brain barrier due to its lipophilic properties.

Baclofen acts as a selective agonist at GABA-B receptors, which are G-protein coupled receptors (metabotropic) distinct from the ionotropic GABA-A receptors targeted by benzodiazepines and barbiturates. Activation of GABA-B receptors leads to:

Presynaptic inhibition: Reduced calcium influx into presynaptic terminals, decreasing the release of excitatory neurotransmitters including glutamate and substance P
Postsynaptic hyperpolarization: Increased potassium conductance, making neurons less excitable
Reduced spinal reflex activity: Decreased monosynaptic and polysynaptic reflex transmission at the spinal level

The net effect is a reduction in muscle tone and spasticity without directly affecting skeletal muscle contractility. Baclofen primarily acts at the spinal cord level, though supraspinal sites also contribute to its antispastic effects.

High-yield for exams

Baclofen is a GABA-B receptor agonist used for spasticity from upper motor neuron lesions (MS, spinal cord injury).
Abrupt discontinuation causes severe withdrawal syndrome: rebound spasticity, seizures, hallucinations, hyperthermia.
Baclofen acts on GABA-B (metabotropic) receptors, not GABA-A (ionotropic) like benzodiazepines.
Most common side effects are drowsiness, dizziness, and muscle weakness.
Intrathecal baclofen delivers drug directly to CSF via implanted pump for severe spasticity unresponsive to oral therapy.
Dose adjustment required in renal impairment; baclofen is primarily renally excreted unchanged.
Baclofen withdrawal from intrathecal pump (malfunction, empty reservoir) is a medical emergency requiring urgent reinstitution.
Overdose presents with CNS depression, hypotonia, respiratory depression, and paradoxical seizures; no specific antidote.

Indications

Baclofen is approved for the management of spasticity resulting from:

Multiple sclerosis: Reduces painful muscle spasms and improves mobility
Spinal cord injury or disease: Trauma, tumors, transverse myelitis, syringomyelia
Cerebral palsy (particularly intrathecal baclofen in severe cases)
Other causes of upper motor neuron syndrome: Stroke, traumatic brain injury

Intrathecal baclofen

For severe spasticity unresponsive to oral therapy, baclofen can be administered intrathecally via an implanted programmable pump. This route delivers drug directly into the cerebrospinal fluid, allowing lower total doses and reduced systemic side effects while achieving greater efficacy. Intrathecal baclofen is particularly useful in patients with:

Severe spasticity affecting activities of daily living
Intolerable side effects from oral baclofen
Inadequate response to maximum oral doses

Off-label uses

Alcohol use disorder (reduces cravings in some studies)
Trigeminal neuralgia
Hiccups (intractable)
Gastroesophageal reflux disease (reduces transient lower esophageal sphincter relaxations)

Pharmacokinetics

Absorption: Rapidly absorbed from the gastrointestinal tract after oral administration. Peak plasma concentrations occur within 2-3 hours. Absorption may be dose-dependent, with reduced bioavailability at higher doses.

Distribution: Widely distributed throughout the body. Crosses the blood-brain barrier, though only about 30% of oral baclofen reaches the CNS. Volume of distribution is approximately 0.7 L/kg. Protein binding is low (30%).

Metabolism: Limited hepatic metabolism. Approximately 15% is metabolized via deamination to inactive metabolites.

Elimination: Primarily renal excretion. About 70-85% is excreted unchanged in urine. Elimination half-life is 3-4 hours in patients with normal renal function. Dose adjustment is required in renal impairment, as accumulation can occur and increase the risk of toxicity.

Special populations: Elderly patients may experience increased CNS side effects due to age-related changes in pharmacokinetics and pharmacodynamics. Renal impairment significantly prolongs half-life and increases exposure.

Adverse effects

Common adverse effects

CNS effects: Drowsiness (10-63%), dizziness, weakness, fatigue, confusion, headache
Gastrointestinal: Nausea, constipation
Hypotonia: Excessive muscle weakness that may impair function
Psychiatric: Insomnia, depression, anxiety, hallucinations (especially at high doses or in elderly)

Serious adverse effects

Seizures: Particularly during withdrawal or overdose
Respiratory depression: Rare, but increased risk with intrathecal administration or overdose
Cardiovascular: Hypotension, bradycardia (uncommon)
Hepatotoxicity: Rare elevations in liver enzymes

Withdrawal syndrome

Abrupt discontinuation of baclofen, especially after prolonged use or high doses, can cause a severe and potentially life-threatening withdrawal syndrome. This is the most high-yield adverse effect for examinations. Symptoms typically begin 1-3 days after cessation and include:

Rebound spasticity (often worse than baseline)
Hyperthermia
Altered mental status, confusion, hallucinations
Seizures (may progress to status epilepticus)
Rhabdomyolysis
Multi-organ failure

Intrathecal baclofen withdrawal is particularly dangerous due to the abrupt loss of high CSF drug concentrations. Pump malfunction, catheter issues, or dosing errors must be identified and corrected urgently. Treatment involves prompt reinstitution of baclofen (oral or intrathecal) and supportive care, including benzodiazepines for seizure control.

Overdose

Baclofen overdose presents with severe CNS and respiratory depression, hypotonia, hypothermia, seizures (paradoxically), and coma. Management is supportive. There is no specific antidote. Hemodialysis may be considered in severe cases with renal impairment.

Contraindications and warnings

Absolute contraindications

Hypersensitivity to baclofen or any formulation component

Relative contraindications and cautions

Renal impairment: Dose reduction required; increased risk of toxicity due to reduced clearance
Seizure disorders: Baclofen may lower seizure threshold; use with caution and monitor closely
Psychiatric disorders: Can exacerbate depression, psychosis, or confusional states
Peptic ulcer disease: May worsen symptoms in some patients
Elderly patients: Increased sensitivity to CNS effects; start with lower doses

Pregnancy and lactation

Baclofen is Pregnancy Category C. Animal studies show increased incidences of omphalocele and incomplete ossification at high doses. Use only if potential benefit justifies potential risk to the fetus. Baclofen is excreted in breast milk in small amounts; caution is advised during lactation.

Withdrawal risk

Patients must be counseled that baclofen should never be stopped abruptly. Gradual tapering over 1-2 weeks (or longer for high doses or prolonged therapy) is essential. For intrathecal baclofen, ensure pump function and fill schedules are maintained.

Activities requiring alertness

Patients should be warned about sedation and CNS depression. Avoid driving, operating machinery, or performing tasks requiring full alertness until response to the drug is known. Concurrent use of alcohol or other CNS depressants significantly increases risk.

Drug interactions

CNS depressants

Concurrent use of baclofen with other CNS depressants produces additive effects:

Alcohol: Enhanced sedation and cognitive impairment
Benzodiazepines: Increased drowsiness, respiratory depression risk
Opioids: Additive respiratory and CNS depression
Tricyclic antidepressants: Increased muscle relaxation and sedation
Antihistamines, sedative-hypnotics: Enhanced sedative effects

Patients should be counseled to avoid or minimize concurrent use and be monitored closely if combination therapy is necessary.

Antihypertensive agents

Baclofen may potentiate the hypotensive effects of antihypertensive medications. Blood pressure should be monitored, especially during initiation or dose escalation.

Levodopa and carbidopa

Concurrent use may increase the risk of CNS side effects, including hallucinations, confusion, and agitation. Monitor for changes in mental status.

Tricyclic antidepressants

May enhance muscle-relaxant effects of baclofen, leading to pronounced hypotonia.

MAO inhibitors

Theoretical risk of CNS and cardiovascular effects; use caution and monitor closely.

Drugs affecting renal function

Medications that impair renal function may decrease baclofen clearance and increase toxicity risk. Dose adjustment may be necessary.

Clinical pearls

Taper, don't stop: The single most important safety consideration is avoiding abrupt discontinuation. Always taper gradually, especially after long-term use or high doses. Educate patients explicitly about withdrawal risks.

Start low, go slow: Begin with low doses (5 mg three times daily) and titrate gradually every 3 days based on response and tolerability. This minimizes sedation and other CNS side effects.

Intrathecal baclofen test dose: Before implanting a pump, a test dose is administered to assess response. A positive response (reduced spasticity with acceptable side effects) predicts benefit from chronic intrathecal therapy.

Pump troubleshooting: Sudden return of spasticity in a patient with an intrathecal pump should prompt immediate evaluation for pump malfunction, catheter disconnection, or medication exhaustion. This is a medical emergency.

Renal dosing: Always adjust dose in renal impairment. Patients on hemodialysis may require supplemental dosing post-dialysis, as baclofen is dialyzable.

Not first-line for muscle spasm: Baclofen is not indicated for skeletal muscle spasm due to musculoskeletal conditions (e.g., low back pain, sprains). It is specific for spasticity from upper motor neuron lesions.

GABA-B vs GABA-A: Remember baclofen acts on GABA-B (metabotropic), not GABA-A (ionotropic). Benzodiazepines, barbiturates, and alcohol act on GABA-A. Baclofen does not have the same potential for abuse as GABA-A agonists, though psychological dependence can occur.

Seizure risk is bidirectional: Baclofen may lower seizure threshold during use, but withdrawal can precipitate seizures even in patients without prior seizure history.

Alcohol use disorder: While not FDA-approved, baclofen has shown promise in some studies for reducing alcohol cravings and consumption. Evidence is mixed, and it is not a standard treatment.

Mnemonic

BACLOFEN withdrawal: Bad spasticity, Agitation, Confusion, Life-threatening seizures, Organ failure (rhabdomyolysis), Fever, Ever taper gradually, Never stop abruptly.

Practice questions

1. A 34-year-old woman with multiple sclerosis has been taking baclofen 80 mg daily for spasticity for the past 6 months. She runs out of medication while traveling and is unable to refill her prescription for 4 days. She presents to the emergency department with severe leg spasms, fever to 39.4°C (103°F), confusion, and visual hallucinations. On examination, she is diaphoretic and agitated with marked lower extremity rigidity. Which of the following is the most appropriate initial management?

Answer: B. This patient is experiencing baclofen withdrawal syndrome after abrupt discontinuation. The presentation of rebound spasticity, hyperthermia, altered mental status, and hallucinations 3-4 days after stopping baclofen is classic. The most important intervention is prompt reinstitution of baclofen (oral or intrathecal) to reverse withdrawal. While benzodiazepines may help control seizures if they occur and supportive care is important, restarting baclofen addresses the underlying cause. The fever and confusion might suggest infection, but the temporal relationship to medication discontinuation and presence of severe spasticity point to withdrawal as the primary diagnosis.

2. A 45-year-old man with paraplegia from a T6 spinal cord injury has severe lower extremity spasticity despite maximum doses of oral baclofen (120 mg daily in divided doses). The spasticity significantly interferes with transfers and causes painful spasms at night. His renal function is normal. Which of the following is the most appropriate next step in management?

Answer: C. This patient has severe spasticity that is inadequately controlled with maximum oral baclofen dosing and significantly impairs function. Intrathecal baclofen, delivered directly into the cerebrospinal fluid via an implanted pump, is indicated for severe spasticity unresponsive to oral medications. It provides superior efficacy with lower total drug doses and reduced systemic side effects. A test dose is given first to confirm response before pump implantation. Increasing oral baclofen beyond 80-120 mg daily rarely provides additional benefit and increases side effects. While adding another agent like tizanidine might be tried, the severity and impact on function make intrathecal therapy the most appropriate option.

3. A 28-year-old woman with cerebral palsy takes baclofen 60 mg daily for spasticity. She is found unconscious at home with an empty bottle of baclofen beside her. In the emergency department, she is obtunded with a Glasgow Coma Scale score of 6, blood pressure 85/50 mmHg, heart rate 52/min, respiratory rate 8/min, and temperature 35.8°C (96.4°F). She has marked hypotonia. Which of the following best describes the appropriate management?

Answer: C. This patient has baclofen overdose presenting with classic features: CNS depression, respiratory depression, hypotension, bradycardia, hypothermia, and hypotonia. There is no specific antidote for baclofen overdose. Management is entirely supportive, including airway protection and mechanical ventilation if needed, intravenous fluids, vasopressors for refractory hypotension, and warming. Flumazenil is a benzodiazepine antagonist and does not reverse baclofen, which acts on GABA-B receptors. Physostigmine is for anticholinergic toxicity, and naloxone is for opioid overdose, neither of which fits this presentation. Baclofen does not cause sodium channel blockade.

Frequently asked questions

How does baclofen work?

Baclofen works by activating GABA-B receptors in the central nervous system, particularly at the spinal cord level. This activation causes presynaptic inhibition of excitatory neurotransmitter release and postsynaptic hyperpolarization, reducing spinal reflex activity and muscle tone. Unlike GABA itself, baclofen crosses the blood-brain barrier effectively, allowing it to reduce spasticity without directly affecting skeletal muscle.

What are the side effects of baclofen?

The most common side effects of baclofen are drowsiness, dizziness, weakness, and fatigue. Gastrointestinal effects like nausea and constipation also occur. Serious adverse effects include seizures (especially during withdrawal), respiratory depression, confusion, and hallucinations at high doses. The most dangerous complication is abrupt withdrawal syndrome, which causes rebound spasticity, seizures, hyperthermia, and altered mental status that can be life-threatening.

Is baclofen a controlled substance?

No, baclofen is not classified as a controlled substance in the United States or most countries. Unlike benzodiazepines or other GABA-A agonists, baclofen has limited abuse potential because it acts on GABA-B receptors. However, physical dependence can develop with chronic use, and abrupt discontinuation causes severe withdrawal syndrome, so it must be tapered gradually when stopping therapy.

What is the difference between baclofen and cyclobenzaprine?

Baclofen is a GABA-B receptor agonist used specifically for spasticity from upper motor neuron lesions like multiple sclerosis and spinal cord injury. Cyclobenzaprine is a centrally-acting muscle relaxant structurally related to tricyclic antidepressants, used for acute musculoskeletal pain and muscle spasm. Baclofen reduces pathological muscle tone from neurological conditions, while cyclobenzaprine treats painful muscle spasms from local musculoskeletal injury or strain.

Can baclofen be stopped suddenly?

No, baclofen should never be stopped suddenly. Abrupt discontinuation, especially after prolonged use or high doses, can cause a severe and potentially life-threatening withdrawal syndrome. Symptoms include rebound spasticity (often worse than baseline), seizures that may progress to status epilepticus, hyperthermia, hallucinations, confusion, and multi-organ failure. Baclofen must be tapered gradually over 1-2 weeks or longer. This is especially critical for intrathecal baclofen, where withdrawal is a medical emergency.

Conditions it is used for

Multiple sclerosis spasticitySpinal cord injury spasticityCerebral palsyStroke with upper motor neuron syndromeTraumatic brain injury spasticityTrigeminal neuralgiaAlcohol use disorderIntractable hiccups

TizanidineDantroleneDiazepam Cyclobenzaprine Gabapentin Pregabalin Botulinum toxin Clonidine

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlus WHO ATC/DDD index: M03BX01

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.

Baclofen